This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

This study has been completed.
Information provided by:
Sociedade Galega de Reumatoloxía Identifier:
First received: March 26, 2007
Last updated: March 27, 2007
Last verified: March 2007
The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.


Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Resource links provided by NLM:

Further study details as provided by Sociedade Galega de Reumatoloxía:

Estimated Enrollment: 240
Study Start Date: January 1997
Study Completion Date: December 2006
Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

  • Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00453128

Meixoeiro Hospital
Vigo, Pontevedra, Spain, 36214
Sponsors and Collaborators
Sociedade Galega de Reumatoloxía
Principal Investigator: José M Pego-Reigosa, MD, PhD Meixoeiro Hospital, Vigo (Pontevedra) SPAIN
  More Information Identifier: NCT00453128     History of Changes
Other Study ID Numbers: SGR1
Study First Received: March 26, 2007
Last Updated: March 27, 2007

Keywords provided by Sociedade Galega de Reumatoloxía:
Calcium Pyrophosphate
associated conditions

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Calcium, Dietary
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on August 18, 2017